Dupilumab治疗后海莉病的改善

IF 1.5 4区医学 Q3 DERMATOLOGY

Journal of Drugs in Dermatology Pub Date : 2025-04-01 DOI:10.36849/JDD.8060

Shravya Kichena, Jocelyn Carnicle, Mara Haseltine

{"title":"Dupilumab治疗后海莉病的改善","authors":"Shravya Kichena, Jocelyn Carnicle, Mara Haseltine","doi":"10.36849/JDD.8060","DOIUrl":null,"url":null,"abstract":"Hailey-Hailey disease (HHD) is a rare, chronic skin disorder characterized by recurrent inflammatory plaques with painful blisters, erosions, and macerations. We report a case of a 40-year-old female with clinical and pathological findings consistent with HHD. After numerous unsuccessful treatments, including the use of antiseptic washes, topical and oral medications, and injections, the patient was started on dupilumab (300 mg/2 mL syringes every 2 weeks). After 4 months of treatment, there was a clearance of plaques and resolution of pain with only minimal residual erythema. This response was maintained with no reported side effects. Dupilumab may be an effective and safe treatment option for refractory HHD, but it necessitates further research. J Drugs Dermatol. 2025;24(4):410-412. doi:10.36849/JDD.8060.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"410-412"},"PeriodicalIF":1.5000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Improvement of Hailey-Hailey Disease Following Administration of Dupilumab.\",\"authors\":\"Shravya Kichena, Jocelyn Carnicle, Mara Haseltine\",\"doi\":\"10.36849/JDD.8060\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hailey-Hailey disease (HHD) is a rare, chronic skin disorder characterized by recurrent inflammatory plaques with painful blisters, erosions, and macerations. We report a case of a 40-year-old female with clinical and pathological findings consistent with HHD. After numerous unsuccessful treatments, including the use of antiseptic washes, topical and oral medications, and injections, the patient was started on dupilumab (300 mg/2 mL syringes every 2 weeks). After 4 months of treatment, there was a clearance of plaques and resolution of pain with only minimal residual erythema. This response was maintained with no reported side effects. Dupilumab may be an effective and safe treatment option for refractory HHD, but it necessitates further research. J Drugs Dermatol. 2025;24(4):410-412. doi:10.36849/JDD.8060.\",\"PeriodicalId\":15566,\"journal\":{\"name\":\"Journal of Drugs in Dermatology\",\"volume\":\"24 4\",\"pages\":\"410-412\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drugs in Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.36849/JDD.8060\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8060","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

海利-海利病（Hailey-Hailey disease，HHD）是一种罕见的慢性皮肤病，其特征是反复出现炎性斑块，伴有疼痛性水疱、糜烂和浸渍。我们报告了一例 40 岁女性的病例，其临床和病理结果均与海利-海利病一致。经过多次治疗（包括使用消毒洗剂、外用和口服药物以及注射）未果后，患者开始使用杜必鲁单抗（300 毫克/2 毫升注射器，每两周一次）。治疗 4 个月后，斑块消失，疼痛减轻，仅残留少量红斑。这种反应得以维持，且未报告有副作用。杜比鲁单抗可能是治疗难治性HHD的一种有效而安全的方法，但仍需进一步研究。J Drugs Dermatol.2025;24(4):410-412. doi:10.36849/JDD.8060.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Improvement of Hailey-Hailey Disease Following Administration of Dupilumab.

Hailey-Hailey disease (HHD) is a rare, chronic skin disorder characterized by recurrent inflammatory plaques with painful blisters, erosions, and macerations. We report a case of a 40-year-old female with clinical and pathological findings consistent with HHD. After numerous unsuccessful treatments, including the use of antiseptic washes, topical and oral medications, and injections, the patient was started on dupilumab (300 mg/2 mL syringes every 2 weeks). After 4 months of treatment, there was a clearance of plaques and resolution of pain with only minimal residual erythema. This response was maintained with no reported side effects. Dupilumab may be an effective and safe treatment option for refractory HHD, but it necessitates further research. J Drugs Dermatol. 2025;24(4):410-412. doi:10.36849/JDD.8060.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Drugs in Dermatology DERMATOLOGY-

CiteScore

2.20

自引率

13.30%

发文量

289

审稿时长

3-6 weeks

期刊介绍： The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.